Antibodies are the principal effector proteins of the immune system, which target and inactivate pathogens. Next generation sequencing of antibodies has led to an abundance of immunoglobulin sequencing (Ig-seq) data becoming available, and a challenging area of research is investigating how we can use this sequencing data to accurately predict the likelihood of an antibody binding to a target. My DPhil project is exploring how we can best use Ig-seq data to improve our ability to design antibody therapeutics, by combining sequence and structural information to more accurately understand and predict antibody binding.